Share on

Global Drug Screening Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Sample Type, End-user, Products & Services and Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 7844
Pages: 175
Formats: report pdf report excel report power bi report ppt

Global Drug Screening Market Size (2022 to 2027)

The global drug screening market size is estimated to be worth USD 10.34 billion by 2027 and USD 6.48 billion in 2022, growing at a CAGR of 9.8% from 2022 to 2027.

Drug screening tests utilize biological samples such as saliva, blood, and hair to detect the presence of drugs or drugs’ metabolites in a person at a certain point in time. The rapid advancements in science and technology result in the invention of various new kinds of drug screening tests that provide better accuracy.

Covid-19 Impact on the global drug screening market:

The outbreak of COVID-19 has an effect all over the world as well on the drug screening market. Drug screening tests are used to determine if a person is under the influence of drugs at a certain point in time. Drug screening is an integral part of deciding drugs present in an individual for proper evaluation and treatment. Drug screening is often done by respective authorities at schools, hospitals, and employment places, for individuals and athletes. In areas of employment, drug screening is done as pre-employment testing for prospective employees.

Due to COVID issues, there are still travel bans and restrictions being continued across the globe, and hence the drug screening market has taken a break from airport testing’s due to travel ban issues around the world. However, the drug screening centers in hospitals are also at risk as COVID patients have been isolated and treated in every hospital allotted worldwide.


The factors that significantly boost the growth of the global drug screening market are the increased prevalence of drug abuse and illegal applications of drugs. Enforcement of stringent laws for drug and alcohol testing contributes to the growth of the drug screening market. The emergence of novel and innovative products into the market due to regulatory approvals is another significant factor that catalyzes the growth of the platelet drug screening business. Increasing concerns over safety at the workplace have made the drug screening tests mandatory at regular intervals. Increasing demand for non-invasive screening devices is boosting the growth of the drug screening market around the world.

The emergence of novel and useful drug testing practices at workplaces such as oral fluid and the availability of technologically advanced pain management facilities and drug management facilities are expedited to offer lucrative growth opportunities for the key players operating in the drug screening market forecast period. Increasing the focus of the various governments worldwide is enforcing stringent laws and increasing the funding to adopt advanced and effective screening devices to curb the illegal use of un-prescripted drugs. Favorable regulatory conditions and easy approvals leading to escalation of R & D activities and rise in product launches are supposed to create more growth opportunities for the stakeholders in the drug screening market.


The critical problem that is restraining the application of drug screening devices is the high costs of the equipment. Notably, the adoption of drug screening devices and testing practices is practiced at a low rate in underdeveloped and developing countries due to budget limitations. Another factor that is challenging the growth of the drug screening market is breath analyzers are unreliable in a significant number of cases. It has a history of providing inaccurate results. Consumption of drugs and alcohol is strictly prohibited. It is very minimal in Islamic nations due to religious reasons, and this is another major factor that is resisting the growth of the global drug screening market.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By sample type, products & services, End-User and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa


This market research report on the global drug screening market has been segmented and sub-segmented based on the sample type, products & services, end-user, and region.

Drug Screening Market Analysis - By Sample Type:

  • Hair
  • Blood
  • Urine
  • Others

Based on the sample type, the urine sample segment occupied the leading shares in 2020. Focus on the early detection of the diseases is likely to propel the growth rate of the market.

Drug Screening Market Analysis - By End-user:

  • Hospitals
  • Workplaces
  • Criminal Justice
  • Law Enforcement

Based on end-user, the workplace segment is expected to grow at a high growth rate, owing to the increasing number of mandatory drug screening tests in the recruitment process of many companies.

Drug Screening Market Analysis - By Products & Services:

  • Breathalyzer
  • Rapid Test Device
  • Immunoassay Analyser
  • Chromatography
  • Others

Based on products & services, the Breathalyser segment is the top contributor to the global market share.

Drug Screening Market Analysis - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America provided the largest drug screening market in 2020 because of the extremely stringent regulations enforced by regulatory agents like the Drug Enforcement Agency (DEA) of the United States in the region. Asia-Pacific region portrays a high growth rate for the recent future.

North America dominates the global drug screening market in revenue terms owing to increasing cases of drug and alcohol abuse and stringent government regulations for drug screening and testing in the region. Popularity and demand for quick testing devices in North America are likely high as the government is expected to regularize the policies for unlawful drug usage.

The market in Europe accounted for the second-highest revenue share in the global drug screening market, followed by markets in the Asia Pacific and Latin America, respectively.

The Asia Pacific market is projected to witness the fastest revenue growth, owing to the increasing number of drug and alcohol addicts, rising disposable income, and growing awareness regarding alcohol and drug screening in emerging economies such as China, India, and Japan.

In the developed markets such as the USA, the UK, Australia, and others, drug tests are considered much more reliable and accurate than simple drug screens. However, these tests are a lot pricier, i.e., USD 200, and take longer to perform, i.e., around 1-7 days. However, these tests are far more in demand for pre-employment services, rehabilitation services, sports & training academy, etc.


Leading market participants in the global drug screening market profiled in this report are Thermo Fisher Scientific Inc. Express Diagnostics Int’l Inc., Abbott Laboratories, Siemens AG, Alere Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Biorad Laboratories Inc., Shimadzu, and Omega Laboratories.


  • Care health America Corporation completed the acquisition of express diagnostics internationally in 2018. Care health has expanded its product portfolio, and even the customers of express diagnostics will have access to the products offered by both companies. Another key objective of their deal is to provide advanced and rapid diagnostics with reduced costs to the people and distribution partners.  
  • Alere Inc. has launched a product called icup RX drug screen 2017. The device is used for conducting urine tests, and it can detect almost five abused or misused prescription drugs. The rapid screening allows the specialists to streamline the testing process and managing patients at de-habilitation centers. Professionals believe that the selection is essential to identify the kind of drug taken by the patient to apply a relative treatment method.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample